Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

4SCAR DLL3 T cells

Preclinical

SShenzhen Geno-Immune Medical Institute

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Glioblastoma of CerebellumNot yet recruiting

Glioblastoma of CerebellumPreclinical

Not yet recruiting

Timeline

Expected Milestones

Q4 2028

PreclinicalNot yet recruiting

Glioblastoma of Cerebellum

NCT07180927

Clinical

Trials by Indication[1]

Glioblastoma of Cerebellum1 trial

4sCAR-DLL3 CAR-T Therapy Targeting Brain Tumors

Not yet recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT07180927·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 4SCAR DLL3 T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 4SCAR DLL3 T cells. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shenzhen Geno-Immune Medical Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SShenzhen Geno-Immune Medical Institute

Related News